SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nektar Therapeutics Q3 2026 net loss widens 57% to $55.65 million

Nektar Therapeutics Q3 2026 net loss widens 57% to $55.65 million Nektar Therapeutics' third-qua

NKTR

Related stories